AstraZeneca India to Launch Datverzo as Q2 Revenue Rises 30%
AstraZeneca Pharma India will launch Datverzo for HR-positive, HER2-negative breast cancer in November 2026 as Q2 FY27 revenue rose 30% to ₹729 crore.
DATOPOTAMAB-DERUXTECAN
AstraZeneca Pharma India will launch Datverzo for HR-positive, HER2-negative breast cancer in November 2026 as Q2 FY27 revenue rose 30% to ₹729 crore.
